There are currently 840 clinical trials in Phoenix, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Phoenix Children's Hospital, GSK Investigational Site, Mayo Clinic Arizona and Mayo Clinic. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of AMDX-2011P in Participants With CAA
NCT05709314
Recruiting
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Associated Retina Consultants, Phoenix, Arizona
Conditions: Cerebral Amyloid Angiopathy
Register for Updates
A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma
NCT06223048
Recruiting
The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).
Gender:
ALL
Ages:
22 years and above
Trial Updated:
07/29/2024
Locations: Associated Retina Consultants, Phoenix, Arizona
Conditions: Primary Open Angle Glaucoma
Register for Updates
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
NCT01526681
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2024
Locations: RANGER & MATCH: Arizona Center for Hand Surgery, Phoenix, Arizona +1 locations
Conditions: Peripheral Nerve Injuries
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Valleywise Health Medical Center, Phoenix, Arizona
Conditions: Ulcerative Colitis
Register for Updates
A Study of AMDX-2011P in Participants With Alzheimer's Disease
NCT06514001
Recruiting
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2024
Locations: Associated Retina Consultants, Phoenix, Arizona
Conditions: Alzheimer Disease
Register for Updates
Reducing COVID-19 Vaccine Hesitancy Among Hispanic Parents
NCT06036134
Recruiting
COVID-19 vaccines are available to children over six months, and these vaccines are powerful tools against this catastrophic pandemic. However, Hispanic/Latino children have lower COVID-19 vaccination rates than White non-Hispanic children .Our team of health communication and public health experts proposes a community-based theory-driven intervention that utilizes culturally-grounded narratives from digital storytelling to reduce Hispanic parents' COVID-19 vaccine hesitancy and increase their c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Arizona State University, Phoenix, Arizona
Conditions: Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice, Narration
Register for Updates
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
NCT00920972
Recruiting
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells. It is also to determine major toxicities from these conditioning regimens, within the first 100 days after transplantation.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
07/19/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
Register for Updates
BiVACOR® Total Artificial Heart Early Feasibility Study
NCT06174103
Recruiting
The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVAC... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2024
Locations: Banner - University Medical Center Phoenix, Phoenix, Arizona
Conditions: Heart Failure, Biventricular Failure
Register for Updates
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
NCT04023331
Recruiting
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: Arizona Oncology Associates, PC, Phoenix, Arizona
Conditions: Breast Cancer
Register for Updates